13/12/2023
A recent study from St Vincent’s Institute of Medical Research reveals promising results in using the rheumatoid arthritis drug baricitinib to slow the progression of type 1 diabetes. Administered within 100 days of diagnosis, the drug effectively preserves insulin production, offering hope for a groundbreaking tablet-based treatment. Early trials demonstrate reduced insulin dependency in participants, marking a potential shift in managing type 1 diabetes.
